X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (506156) 506156
Newsletter (127675) 127675
Publication (34924) 34924
Newspaper Article (14147) 14147
Book Review (3102) 3102
Magazine Article (2160) 2160
Book Chapter (957) 957
Conference Proceeding (940) 940
Book / eBook (834) 834
Dissertation (479) 479
Transcript (457) 457
Web Resource (381) 381
Trade Publication Article (349) 349
Reference (170) 170
Government Document (104) 104
Streaming Video (93) 93
Data Set (55) 55
Paper (38) 38
Journal / eJournal (35) 35
Presentation (13) 13
Report (7) 7
Poster (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (410316) 410316
antineoplastic agents (213896) 213896
cancer (210598) 210598
antimitotic agents (197274) 197274
female (196280) 196280
index medicus (181934) 181934
male (161807) 161807
oncology (153155) 153155
care and treatment (125188) 125188
middle aged (124805) 124805
research (115395) 115395
animals (115144) 115144
antineoplastic agents - therapeutic use (104068) 104068
antineoplastic combined chemotherapy protocols - therapeutic use (103054) 103054
aged (102815) 102815
adult (101436) 101436
antineoplastic agents - pharmacology (96592) 96592
chemotherapy (92792) 92792
oncology, experimental (63702) 63702
cell line, tumor (63280) 63280
treatment outcome (62686) 62686
mice (61946) 61946
reports (50865) 50865
pharmacology & pharmacy (49808) 49808
health aspects (46885) 46885
apoptosis (46799) 46799
antineoplastic agents - administration & dosage (41580) 41580
analysis (41082) 41082
combined modality therapy (39926) 39926
prognosis (39536) 39536
antineoplastic agents - adverse effects (39138) 39138
neoplasms - drug therapy (38456) 38456
drug therapy (38080) 38080
universities and colleges (34963) 34963
apoptosis - drug effects (33405) 33405
breast neoplasms - drug therapy (33314) 33314
therapy (33217) 33217
breast cancer (32949) 32949
antineoplastic agents - chemistry (32039) 32039
hematology (31942) 31942
drugs (31848) 31848
aged, 80 and over (31416) 31416
dose-response relationship, drug (30622) 30622
antineoplastic combined chemotherapy protocols - adverse effects (29772) 29772
tumors (28709) 28709
neoplasm staging (28567) 28567
cell proliferation - drug effects (28077) 28077
adolescent (27535) 27535
retrospective studies (26619) 26619
biochemistry & molecular biology (26474) 26474
metastasis (26037) 26037
lung neoplasms - drug therapy (25427) 25427
expression (25319) 25319
chemistry, medicinal (24220) 24220
carcinoma (23546) 23546
time factors (23414) 23414
survival rate (22917) 22917
disease-free survival (22833) 22833
cell survival - drug effects (22449) 22449
tumor cells, cultured (22424) 22424
cisplatin - administration & dosage (22226) 22226
survival (22157) 22157
medicine & public health (22039) 22039
cisplatin (21817) 21817
radiotherapy (21748) 21748
child (21243) 21243
antineoplastic combined chemotherapy protocols - administration & dosage (21038) 21038
follow-up studies (20781) 20781
genetic aspects (20560) 20560
surgery (20514) 20514
survival analysis (19739) 19739
drug administration schedule (19658) 19658
drug screening assays, antitumor (19422) 19422
rats (19330) 19330
article (19196) 19196
doxorubicin - administration & dosage (18710) 18710
chemotherapy, adjuvant (18538) 18538
medical research (18362) 18362
pharmaceutical industry (18310) 18310
antineoplastic agents, phytogenic - pharmacology (18240) 18240
cells (18198) 18198
fluorouracil - administration & dosage (18023) 18023
breast neoplasms - pathology (17920) 17920
drug resistance, neoplasm (17410) 17410
antineoplastic agents - chemical synthesis (17215) 17215
in-vitro (16721) 16721
clinical trials as topic (16410) 16410
risk factors (16318) 16318
clinical trials (16288) 16288
hematology, oncology and palliative medicine (16187) 16187
structure-activity relationship (15915) 15915
cyclophosphamide - administration & dosage (15300) 15300
mice, nude (15288) 15288
molecular structure (14809) 14809
leukemia (14670) 14670
trial (14664) 14664
cell biology (14638) 14638
cytotoxicity (14536) 14536
remission induction (14325) 14325
breast-cancer (14064) 14064
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (447) 447
Online Resources - Online (375) 375
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (55) 55
Collection Dvlpm't (Acquisitions) - Vendor file (47) 47
Collection Dvlpm't (Acquisitions) - Closed Orders (35) 35
UofT at Mississauga - Stacks (16) 16
Gerstein Science - Periodical Stacks (15) 15
Scarborough Hospital - Online (6) 6
Chemistry (A D Allen) - Stacks (5) 5
Scarborough Hospital - Birchmount (5) 5
Gerstein Science - Bindery (4) 4
Lakeridge Health Sciences - Online (4) 4
UTL at Downsview - May be requested (4) 4
Robarts - Stacks (3) 3
St. Michael's Hospital - Stacks (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Reference (3) 3
Credit Valley Hospital - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (2) 2
East Asian (Cheng Yu Tung) - Reference (2) 2
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Reference (2) 2
Scarborough Hospital - General (2) 2
Sunnybrook Health Sciences Centre - Online (2) 2
Baycrest Hospital - Wellness Library (1) 1
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - Course Reserves (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Theses (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Pharmacy (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Missing (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Periodicals (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT Schools - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
Women's College Hospital - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (603697) 603697
Japanese (16582) 16582
French (7713) 7713
Chinese (7479) 7479
Russian (5115) 5115
German (4495) 4495
Polish (1541) 1541
Spanish (1361) 1361
Italian (1138) 1138
Hungarian (708) 708
Czech (676) 676
Danish (382) 382
Portuguese (325) 325
Dutch (269) 269
Swedish (250) 250
Norwegian (226) 226
Ukrainian (179) 179
Hebrew (160) 160
Korean (156) 156
Finnish (139) 139
Bulgarian (124) 124
Croatian (116) 116
Serbian (111) 111
Slovak (84) 84
Romanian (78) 78
Lithuanian (29) 29
Turkish (26) 26
Bosnian (13) 13
Greek (7) 7
Afrikaans (3) 3
Icelandic (3) 3
Slovenian (3) 3
Amharic (1) 1
Arabic (1) 1
Catalan (1) 1
Kurdish (1) 1
Manx (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2009, Current clinical oncology, ISBN 9781603270861, xxviii, 637
A panel of international authorities analyzes in depth in this book the role of the lymphovascular system in the spread of cancer. They also summarize the... 
Neoplasms Invasiveness | Neoplasm Metastasis | Clinical & internal medicine | Metastasis | Lymphangiogenesis - drug effects | Pathology | Oncology | Medicine & Public Health | Radiotherapy | Surgical Oncology
Book
Anti-cancer drug design, ISSN 0266-9536, 1985
Journal
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | APOPTOSIS | ANTIINFLAMMATORY ACTIVITY | ACTIVATION | CELL-CYCLE ARREST | PROLIFERATION | METASTATIC COLORECTAL-CANCER | IN-VITRO | ONCOLOGY | ENDOTHELIAL-CELLS | PHARMACOLOGY & PHARMACY | EA.hy 926 endothelial cells | INHIBITORS | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Cancer chemotherapy and pharmacology, ISSN 0344-5704
Journal
2007, Cancer drug discovery and development, ISBN 1588296725, xiv, 455
Book
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Anti-cancer drugs, ISSN 0959-4973, 1990
Journal
2008, ISBN 9780123694485, xv, 473 p., [27] p. of plates
The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes... 
Antineoplastic agents | Clinical & internal medicine | Design | Development
Book
2008, 1. Aufl., Cancer drug discovery and development series, ISBN 1934115290, xxi, 419
Book
2011, 8th ed., ISBN 160831782X, xiv, 875
Skeel's Handbook of Cancer Chemotherapy combines in one place the most current rationale and specific details necessary to safely administer chemotherapy for... 
Chemotherapy | Cancer | Handbooks, manuals, etc
Book
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | PLUS DEXAMETHASONE | ABNORMALITIES | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | DELETION | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 08/2014, Volume 90, Issue 3, pp. 212 - 225
This study was aimed at investigating the reversal effect of oroxylin A, a naturally bioactive monoflavonoid separated and purified from , in human chronic... 
PI3K/Akt/NF-κB pathway | Oroxylin A | CXCL12/CXCR4 axis | K562/ADM | Reversal effect | PI3K/Akt/NF-kappa B pathway | DOUBLING TIME | MARROW | MEDIATED MULTIDRUG-RESISTANCE | DOWN-REGULATION | CXCR4 | CXCL12/OCCR4 axis | MESENCHYMAL STROMAL CELLS | IN-VITRO | CANCER DEVELOPMENT | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | NF-KAPPA-B | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Humans | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Proteins - antagonists & inhibitors | Flavonoids - adverse effects | Neoplasm Proteins - metabolism | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antineoplastic Agents, Phytogenic - administration & dosage | RNA Interference | Female | Receptors, CXCR4 - genetics | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Neoplasm Proteins - genetics | Leukemia, Myeloid, Chronic-Phase - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Antineoplastic Agents, Phytogenic - adverse effects | Doxorubicin - administration & dosage | Receptors, CXCR4 - antagonists & inhibitors | Leukemia, Myeloid, Chronic-Phase - drug therapy | Random Allocation | Receptors, CXCR4 - metabolism | Antibiotics, Antineoplastic - administration & dosage | Phosphatidylinositol 3-Kinase - chemistry | Xenograft Model Antitumor Assays | Animals | Chemokine CXCL12 - metabolism | Antibiotics, Antineoplastic - therapeutic use | Neoplasm Proteins - agonists | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Receptors, CXCR4 - agonists | Mice | Antineoplastic Agents, Phytogenic - pharmacology | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Anthracyclines | Index Medicus
Journal Article